MRK - Liquidia Corporation: A Complicated Tale

2024-02-15 11:35:43 ET

Summary

• Liquidia Corporation shares rallied over 80% after an appeals court invalidated the patent of rival United Therapeutics, potentially paving the way for approval of its PAH and PH-ILD medication Yutrepia.
• However, the FDA recently extended the original action data on that marketing application late in January.
• The company has faced legal battles with United Therapeutics but still should be able to gain full FDA approval for Yutrepia, hopefully in the first half of 2024.
• The complicated tale around Liquidia is highlighted in the paragraphs below.

Loyalty to country ALWAYS. Loyalty to government, when it deserves it .”? Mark Twain.

For further details see: